Early detection and innovative biologic treatment can prevent hospitalizations, improve quality of life, and extend the ...
Researchers estimate the number of people globally living with chronic obstructive pulmonary disease (COPD) will hit 600 million by 2050. There are certain risk factors for COPD, including obesity and ...
To keep up with COPD research and care developments, the 2026 Global Initiative for Chronic Obstructive Lung Disease report ...
For patients with chronic obstructive pulmonary disease (COPD), the Global Initiative on Obstructive Lung Disease recommends long-term term pharmacologic and nonpharmacologic therapies based on each ...
Ensifentrine had favorable efficacy and safety profiles in two phase 3 trials. Verona Pharma is prepared for launch upon FDA approval. The FDA is expected to make a decision on ensifentrine to treat ...
Angiogram of an MI (left) and a normal coronary artery (right) Inhaled anticholinergic agents, the most common treatment for chronic obstructive pulmonary disease (COPD), may increase the risk of ...
New York, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Anti-Asthmatics And COPD Drugs Global Market Report 2020-30: Covid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback